Bias-force guided simulations combined with experimental validations towards GPR17 modulators identification

• Published in: Biomedicine & pharmacotherapy Vol. 160; p. 114320
• Main Authors: Kari, Sana, Murugesan, Akshaya, Thiyagarajan, Ramesh, Kidambi, Srivatsan, Razzokov, Jamoliddin, Selvaraj, Chandrabose, Kandhavelu, Meenakshisundaram, Marimuthu, Parthiban
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.04.2023; Elsevier
• Subjects: Bias-force simulation; Forskolin-stimulated cAMP accumulation; GPR17; Humans; Lactones; Orphan-GPCRs; Pyridines; Receptors, G-Protein-Coupled - metabolism; Remyelination; GPR17; Orphan-GPCRs; Forskolin-stimulated cAMP accumulation; Bias-force simulation; Remyelination
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.114320

Glioblastoma Multiforme (GBM) is known to be by far the most aggressive brain tumor to affect adults. The median survival rate of GBM patient’s is < 15 months, while the GBM cells aggressively develop resistance to chemo- and radiotherapy with their self-renewal capacity which suggests the pressing need to develop novel preventative measures. We have recently proved that GPR17 —an orphan G protein-coupled receptor— is highly expressed on the GBM cell surface and it has a vital role to play in the disease progression. Despite the progress made on GBM downregulation, there still remain difficulties in developing a promising modulator for GPR17, till date. Here, we have performed robust virtual screening combined with biased-force pulling molecular dynamic (MD) simulations to predict high-affinity GPR17 modulators followed by experimental validation. Initially, the database containing 1379 FDA-approved drugs were screened against the orthosteric binding pocket of the GPR17. The external bias-potentials were then applied to the screened hits during the MD simulations which enabled to predict a spectrum of rupture peak force values that were used to select four approved drugs –ZINC000003792417 (Sacubitril), ZINC000014210457 (Victrelis), ZINC000001536109 (Pralatrexate) and ZINC000003925861 (Vorapaxar)– as top hits. The hits selected turns out to demonstrate unique dissociation pathways, interaction pattern, and change in polar network over time. Subsequently the selected hits with GPR17 were measured by inhibiting the forskolin-stimulated cAMP accumulation in GBM cell lines, LN229 and SNB19. The ex vivo validations shows that Sacubitril drug can act as a full agonist, while Vorapaxar functions as a partial agonist for GPR17. The pEC50 of Sacubitril was identified as 4.841 and 4.661 for LN229 and SNB19, respectively. Small interference of the RNA (siRNA)– silenced the GPR17 to further validate the targeted binding of Sacubitril with GPR17. In the current investigation, we have identified new repurposable GPR17 specific drugs which are likely to increase the opportunity to treat orphan deadly diseases. •FDA approved drugs repurposed for GPR17 modulation.•Biased MD simulations predicted high-affinity drugs specific towards GPR17 modulation.•An unique dissociation pathways and interaction pattern demonstrated by the selected hits.•Sacubitril drug can act as a full agonist, while Vorapaxar function as a partial agonist for GPR17.•Sacubitril activate Gαi protein subfamily and inhibit cAMP in GPR17 signaling in GBM cells.